Biogen up 5% after EMA recommends Leqembi for early Alzheimer’s disease
EST Biogen (BIIB) up 5% after EMA recommends Leqembi for early Alzheimer’s disease Published first on TheFly – the ultimate ...
Needham biotech analysts hold an analyst/industry conference call
Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including ...
BioSpace4d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
JCN Newswire5h
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
ALZFORUM17h
Tau Modification Drugs Take a Hit with Negative Trial
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...
FierceBiotech2d
Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
pharmaphorum3d
Four ways Biogen is tackling digital innovation in neurological disease
Biogen was one of the first biotech companies ... the sort of cooperation that Hadjiat sees personified at the Frontiers conference. “When you go around and meet with people, that's what I ...
Le Lézard18h
Small Businesses, Big Future: AI-Powered Hookle App Fuels Sustainable Growth for 30 Million U.S. Micro-Businesses
Hookle, a Finland-based tech company, is advancing sustainable growth for over 30 million U.S. micro-businesses with its AI-powered social media marketing app. By simplifying digital marketing, Hookle ...
pharmaphorum3d
After EU setback, Eisai/Biogen build case for Leqembi
Eisai and Biogen have reported data showing that the ... Now, data reported at the Alzheimer's Association International Conference (AAIC) showed that the gap between the drug and control widened ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Papa John's cut at KeyBanc on longer road to recovery
Investing.com -- KeyBanc Capital Markets downgraded Papa John’s International (PZZA) from Overweight to Sector Weight on Thursday, citing a prolonged path to recovery for the pizza chain.
Le Lézard21h
MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced R&D Leader and Accomplished Biotechnology Executive, as Entrepreneur Partner
Prior to ATP, Dr. Ehlers was Executive Vice President for Research and Development at Biogen, where he significantly grew and diversified Biogen's clinical portfolio and advanced more than 20 novel ...